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thromboembolism. By analyzing the correlation of transthoracic echocardiography
parameters and atrial ﬁbrillation thromboembolism risk assessment indicators
(CHADS2 and CHA2DS2-VASc), a new prediction method of risk of stroke in patients
with atrial ﬁbrillation.
Methods: 304 patients that diagnosed with atrial ﬁbrillation in our hospital from
October 2010 to October 2012, and score to each patient according to standard of
CHADS2 and CHA2DS2-VASc. Patients were divided into low, medium and high-risk
groups. After admission, each patient underwent transthoracic ultrasound echocardi-
ography, internal diameter of right ventricle, interventricular septum thickness, left
ventricular internal diameter, left ventricular posterior wall, right ventricular outﬂow
tract width, aortic root diameter, left atrial diameter, pulmonary artery diameter, EDT
(deceleration time of E wave), speed of aortic valve ﬂow and the pulmonary valve
oriﬁce ﬂow, left ventricular ejection fraction (LVEF). We analysis correlation of
ultrasound heartbeat graph parameters and thromboembolic risk scoring by using
Spearman rank.
Results: (1) The ultrasound indicators that has a signiﬁcant correlation with CHADS2
score are: interventricular septal thickness, left ventricular posterior wall thickness, left
atrial diameter, pulmonary artery diameter, right ventricular diameter, the inner
diameter of the aortic root, LVEF. (2) The ultrasound indicators that has a signiﬁcant
correlation with CHA2DS2-VASc score are: Interventricular septal thickness, left
ventricular posterior wall thickness, left atrial diameter, pulmonary artery diameter,
aortic valve ﬂow velocity, LVEF.
Conclusions: With the CHADS2 and CHA2DS2-VASc score increased, cardiac
ultrasound showed the enlargement of left atrium, left ventricular hypertrophy,
pulmonary artery diameter widened and LVEF decreased. In addition, the internal
diameter of right ventricle, aortic root diameter is associated with CHADS2 score;
aortic valve ﬂow velocity is associated with CHA2DS2-VASc score. It prompted that
the echocardiographic indexs such as thickness of interventricular septum, posterior
wall, left atrial diameter, diameter of pulmonary artery, aortic valve ﬂow rate and
LVEF value may be the identiﬁcation index of thromboembolism risk in non-valvular
atrial ﬁbrillation patients.
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Objectives: Atrial ﬁbrillation (AF) is associated with a signiﬁcantly high risk of stroke
and systemic embolisms, several scoring system are currently used to stratify
thromboembolic risk. We evaluate the predictive power of different scoring system to
identify the suitable scoring system for Chinese atrial ﬁbrillation patients.
Methods: 425 consecutive patients treated in our hospital with paroxysmal or
persistent atrial ﬁbrillation are selected. The clinical data, such as gender, age, blood
pressure (BP), blood lipids, LVEF, history of smoking, embolism, heart failure (HF),
diabetes mellitus (DM), coronary heart disease (CHD), hyperthyroidism, valvular
heart disease (VHD), myocardial infarction (MI), peripheral arterial disease (PAD),
large aortic plaque, are collected for each patient. Telephone follow-up are done for
each patient, the patients with deﬁnitive stroke are deﬁned as stroke positive group.
Above all, 8 scoring system (the original CHADS2 score, modiﬁed CHADS2 score,
Framingham score, Rietbrock modiﬁed score, CHA2DS2-VASc score, 2006 Nice
score, ACC/AHA/ESC score, Eighth Edition ACCP) are used to stratify thrombo-
embolic risk for each patient.
Results: All 426 patients (273 male, 153 female) include 45 cases with stroke,
20 cases with DM, 21 cases with HF, 180 cases with hypertension, 54 cases with
CHD, 31 cases with hyperthyroidism, 34 cases with VHD, 2 cases with TIA, 48 cases
with smoking history. There are signiﬁcant statistically differences between 8 scoring
systems, the ROC curve area of each scoring system are calculated. Original CHADS2
score (Az¼0.917, <1.0,>0.9) have higher accuracy. The six scoring system: modiﬁed
CHADS2 score (Az¼0.864); Rietbrock modiﬁed score (Az¼0.707); CHA2DS2-
VASc (Az¼0.789);2006 Nice (Az¼0.847), ACC/AHA/ESC (Az¼0.883), Eighth
Edition ACCP (Az¼0.886) have moderate accuracy. Whereas Framingham score
(Az¼0.508, <0.7, >0.5) have lower accuracy. The descending accuracy order of the 8
scoring systems is original CHADS2, Eighth Edition ACCP, ACC/AHA/ESC,
modiﬁed CHADS2, 2006 Nice, CHA2DS2-VASc, Rietbrock modiﬁed score,
Framingham score.
Conclusions: The factors or risk stratiﬁcation of the 8 scoring systems is different,
which lead to the different predictive power of same patient. The Original CHADS2
have a higher accuracy and are most suitable scoring system for Chinese atrial
ﬁbrillation patients.
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Objectives: The aims of this study were to evaluate the relationship of the CHADS2
and CHA2DS2-VASc scores with left atrial (LA) thrombus detected by trans-
esophageal echocardiographic and to compare these two risk stratiﬁcation schemes
with respect to their ability to predict LA thrombus in Chinese patients with
nonvalvular atrial ﬁbrillation.C160 JACC Vol 64/16/Suppl C j October 16–1Methods: Transesophageal echocardiograms of 2112 patients (mean age 57.511.8
years; 32% female; 1750 paroxysmal AF) with nonvalvular atrial ﬁbrillation were
retrospectively reviewed for LA thrombus. The patients’ CHADS2 and CHA2DS2-
VASc risk scores and categories were also calculated.
Results: Transesophageal echocardiography revealed LA thrombi in 69 (3.3%)
patients. Using CHADS2, LA thrombus was found in 2.5% of the low-risk group,
3.7% of the intermediate-risk group and 4.1% of the high-risk group (P¼0.23). Using
CHA2DS2-VASc, LA thrombus was found in 1.8% of the low-risk group, 3.5% of the
intermediate-risk group and 4.0% of the high-risk group (P¼0.06). The frequency of
patients with LA thrombi fell into the low-intermediate-risk group classiﬁed based on
the CHADS2 and CHA2DS2-VASc score were 76.8% and 49.3%, respectively. The
c-statistics for predicting LA thrombi with CHADS2 and CHA2DS2-VASc were 0.56
(95% CI 0.49-0.63) and 0.58 (95% CI 0.52-0.65), respectively.
Conclusions: Both CHA2DS2-VASc and CHADS2 scores may have limited value for
predicting LA thrombus in Chinese patients with nonvalvular atrial ﬁbrillation.
Further research is needed to examine their true predictive value.
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Objectives: Atrial ﬁbrillation (AF) is the most commonly encountered sustained
cardiac arrhythmia in medical practice and it is associated with a risk of thrombo-
embolic events or other complications, especially for asymptomatic patients who may
not receive therapy at the earliest. In patients with an implantable device, the inte-
grated home monitoring (HM) technology may provide relevant notiﬁcations for
detection of supra-ventricular arrhythmias (SVA): a treatment can be initiated or
optimized directly after a new onset of SVA. The French randomized, multicenter
SETAM trial assessed the impact of HM on detection and treatment of SVA.
Methods: Patients implanted with a dual chamber pacemaker were enrolled in the
study at hospital discharge if they had a sinusal rhythm at enrollment, no antiar-
rhythmic, anticoagulant or dual-antiplatelet therapy, and if they had a CHA2DS2-
VASc score for stroke risk of 2 or more. The patients were randomly assigned to an
active group, followed by Biotronik HM, or a control group without HM surveillance.
The primary criteria was the comparison of the time from enrollment to the ﬁrst
SVA-related intervention between the groups.
Results: A total of 595 patients in 58 centers (mean age¼798 y.o, 63% male, mean
CHA2DS2-VASc score¼3.71.2) were followed during 12.83.3 mo. There was no
difference in the baseline clinical characteristics between the groups. The most
prevalent concomitant co-morbidities were hypertension (82% patients), diabetes
(29%) and vascular disease (24%). Implantation indications were atrio-ventricular
blocks in 77% of patients, sinus node disease in 20% and others in 3%. The global
SVA incidence was 25% (29% in the active group vs 22% in the control group,
P¼ns). A therapy (drugs or ablation) was instituted for 49/291 patients (17%) in the
active group vs 43/304 patients (14%) in the control group (P¼ns). The median time
from enrollment to the ﬁrst therapy for SVA was 114 [44; 241] days in the active
group vs 224 [67; 366] days in the control group, representing a median gain of
110-days in SVA management (50% reduction, P¼0.01). Over these 92 patients, 54
had AF (59%) and 38 had ﬂutter or atrial tachyarrhythmia (41%). Anticoagulation
was initiated in 80% of patients and antiarrhythmic drugs in 55%. In the active
group, 93% of the notiﬁcations transmitted by HM were appropriate for SVA
detection. The remaining 7% were inappropriate for SVA (over-sensing, noise or
non-sustained VT).
Conclusions: The SETAM study demonstrated that HM allows earlier detection and
treatment of SVA in patients implanted with pacemakers. It suggests that HM could be
expanded to a maximum of patients in daily clinical practice in order to optimize their
SVA management. The next step is to report how early detection of SVA with HM
can possibly improve the patients clinical outcome.
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Objectives: This study is to evaluate the potential cardiac dysfunction in patients with
pacemaker implantation by expression of MicroRNA423-5p and BNP detection.
Methods: A total of 162 patients were recruited and divided into 3 groups: group A
(45 patients with heart failure), group B (48 patients with normal heart function)
and group C (69 patients with pacemaker implantation). Expressions of BNP and9, 2014 j GW-ICC Abstracts/Cardiovascular Disease Clinical Research
